Is CYUXF or MRK a better dividend investment in 2026?

CYUXF currently yields 1555.21% with a 5% 5-year dividend growth rate. MRK yields 2.76% with 8.2% growth. The better choice depends on your goal: CYUXF offers higher current income.

What is the dividend yield difference between CYUXF and MRK?

CYUXF has a forward dividend yield of 1555.21% ($2.00/share annually). MRK yields 2.76% ($3.32/share annually). The yield gap is 1552.45 percentage points.

Home › Compare › CYUXF vs MRK

CYUXF vs MRK: Dividend Comparison 2026

CYUXF yields 1555.21% · MRK yields 2.76%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CYUXF wins by $975847659.21M in total portfolio value

INVESTMENT

TIME HORIZON10 years

CYUXF

● Live price

1555.21%

Share price

$0.13

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$975847659.27M

Annual income

$866,274,478,346,787.00

Full CYUXF calculator →

MRK

Merck & Co. Inc.

● Live price

2.76%

Share price

$120.31

Annual div

$3.32

5Y div CAGR

32.7%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$56.8K

Annual income

$9,798.13

Full MRK calculator →

Portfolio growth — CYUXF vs MRK

📍 CYUXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CYUXF	MRK
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CYUXF + MRK cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CYUXF pays

MRK pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYUXF

Annual income on $10K today (after 15% tax)

$132,192.85/yr

After 10yr DRIP, annual income (after tax)

$736,333,306,594,768.90/yr

MRK

Annual income on $10K today (after 15% tax)

$234.56/yr

After 10yr DRIP, annual income (after tax)

$8,328.41/yr

At 15% tax rate, CYUXF beats the other by $736,333,306,586,440.50/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYUXF + MRK for your $10,000?

CYUXF: 50%MRK: 50%

100% MRK50/50100% CYUXF

Portfolio after 10yr

$487923829.66M

Annual income

$433,137,239,178,292.56/yr

Blended yield

88.77%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CYUXF

No analyst data

Altman Z

-30.0

Piotroski

0/9

MRK

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$128.54

+6.8% upside vs current

Range: $100.00 — $150.00

Altman Z

4.0

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYUXF buys

MRK buys

No recent congressional trades found for CYUXF or MRK in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCYUXFMRK

Forward yield	1555.21% ✓	2.76%
Annual dividend / share	$2.00	$3.32 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	32.7% ✓
Portfolio after 10y	$975847659.27M ✓	$56.8K
Annual income after 10y	$866,274,478,346,787.00 ✓	$9,798.13
Total dividends collected	$967898964.97M ✓	$28.9K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: CYUXF vs MRK ($10,000, DRIP)

Year	CYUXF Portfolio	CYUXF Income/yr	MRK Portfolio	MRK Income/yr	Gap
1← crossover	$166,221	$155,521.00	$11,206	$366.19	+$155.0K → CYUXF
2	$2,593,824	$2,415,967.72	$12,650	$502.35	+$2.58M → CYUXF
3	$38,009,397	$35,234,004.67	$14,407	$694.19	+$37.99M → CYUXF
4	$523,204,886	$482,534,832.18	$16,585	$967.82	+$523.19M → CYUXF
5	$6,767,457,577	$6,207,628,348.73	$19,342	$1,363.89	+$6767.44M → CYUXF
6	$82,281,672,964	$75,040,493,356.77	$22,913	$1,947.19	+$82281.65M → CYUXF
7	$940,728,061,028	$852,686,670,956.12	$27,662	$2,823.89	+$940728.03M → CYUXF
8	$10,117,592,356,386	$9,111,013,331,086.03	$34,159	$4,173.35	+$10117592.32M → CYUXF
9	$102,404,841,981,432	$91,579,018,160,098.60	$43,337	$6,308.80	+$102404841.94M → CYUXF
10	$975,847,659,266,919	$866,274,478,346,787.00	$56,776	$9,798.13	+$975847659.21M → CYUXF

CYUXF vs MRK: Complete Analysis 2026

CYUXF — Stock

BC Moly Ltd., an exploration stage company, engages in the exploration and development of mineral resource properties in Canada. It holds a 100% interest in the Storie molybdenum property located in the Liard Mining Division, British Columbia. BC Moly Ltd. was formerly known as Columbia Yukon Explorations Inc. and changed its name to BC Moly Ltd. in September 2014. The company was incorporated in 1984 and is headquartered in Vancouver, Canada. BC Moly Ltd. is a subsidiary of 1095474 B.C. Ltd.

Full CYUXF Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →

📬

Get this CYUXF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYUXF vs SCHD CYUXF vs JEPI CYUXF vs O CYUXF vs KO CYUXF vs MAIN CYUXF vs JNJ CYUXF vs ABBV CYUXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.